- ACME ABC
Trial Status
In follow-up
Cancer Type
Biliary tract cancer
Protocol Title
Australian Comprehensive Molecular Evaluation of Advanced Biliary Cancer (ACME ABC) Trial
Purpose of the Study
Biliary cancer (BC) remains a rare but important cause of cancer related mortality. Surgical resection is the only potentially curative treatment; however, the majority of patients present with advanced biliary cancer (ABC) are not surgical candidates. Instead, these patients are offered palliative chemotherapy. The median survival of patients with ABC is between 1-2 years.
The ACME ABC study will review the feasibility and potential benefit of instituting routine comprehensive molecular profiling of patients with ABC using either fresh, frozen or archival tissue obtained at the time of routine diagnostic tests.
Contact email
Detailed information available
Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.
Study Chairs
Dr Daniel Croagh
Dr Owen McKay
funding
2021 AGITG-Pancare Cholangiocarcinoma Idea Generation Workshop Grant
Trial Status
In follow-up
Cancer Type
Biliary tract cancer
